Cognitive Dysfunction
Conditions
Keywords
postoperative cognitive decline
Brief summary
Postoperative cognitive impairment develops in the early and continues in the late postoperative period; it is manifested by impaired memory, attention, concentration and other higher cortical functions (thinking, speech). Early studies demonstrated the positive impact of perioperative administration of Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), which prevented impairments of intelligence, speech, and attention after cardiac surgery, both in conditions of cardiopulmonary bypass and on a working heart. The aim of the present study is to evaluate the safety and efficacy of Cytoflavin for the prevention of cognitive disorders after major surgeries performed in elderly patients.
Detailed description
Cytoflavin® (Inosine + Nicotinamide + Riboflavin + Succinic Acid) is a combination drug, which improves coronary and cerebral blood flow, activates metabolic processes in the central nervous system, restores impaired consciousness, promotes regression of neurological symptoms and improvement of cognitive functions of the brain. It has a quick awakening effect in post-anesthetic depression of consciousness. The positive effect of Cytoflavin® on cognitive function has been previously shown in patients with dyscirculatory encephalopathy and acute stroke, as well as in a population of patients during cardiac surgery in cardiopulmonary bypass and working heart. The present study aims to evaluate the opportunity of prevention of postoperative cognitive decline by administration of Cytoflavin® at a sequential regimen, starting from intravenous infusions and followed by oral intake during 1 month. Study objectives: 1. To study the efficacy of Cytoflavin® administered in elderly patients age for the prevention of cognitive decline after major surgery. 2. To study the safety and tolerability of Cytoflavin® in elderly patients for after major surgery.
Interventions
DRUGCytoflavin® solution
Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
DRUGCytoflavin® enteric-coated tablet
2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
DRUGPlacebo solution
Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
DRUGPlacebo enteric-coated tablet
2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
Sponsors
POLYSAN Scientific & Technological Pharmaceutical Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
60 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent 2. Men and women aged 60-80 years, inclusive. 3. Planned cardiac surgery, which does not assume the use of a cardiopulmonary bypass. 4. Planned or delayed orthopedic surgery (hip joint endoprosthetics, osteosynthesis for fractures of the proximal third of the hip, etc.), under general or combined anesthesia. 5. Legal capacity of the patient 6. Absence of dementia (MoCA≥17, MMSE≥19) 7. Lack of reproductive potential or 8. Consent to use adequate methods of contraception
Exclusion criteria
1. Hypersensitivity to any component of the study drug 2. Emergency surgery 3. Repeated surgery or reoperation 4. Anesthesia risk ASA≥5 5. Severe visual or hearing impairment which impedes the performance of neuropsychological tests 6. Operation under general anesthesia in the previous 3 months 7. Severe renal failure requiring replacement of renal function (dialysis) 8. Severe hepatic failure (class C and above in Child-Pugh) 9. Chronic obstructive pulmonary disease 10. Terminal stage of other chronic incurable diseases 11. Decompensated diabetes 12. A history of oncological diseases, mental illness, HIV infection, syphilis, tuberculosis, alcohol or drug addiction 13. The use of 5 or more units of alcohol per week in the previous 3 months 14. Diagnosis of mental or neurodegenerative disease (e.g. schizophrenia, Parkinson's disease, clinically manifest depression) 15. Permanent intake of psychotropic drugs (neuroleptics, tranquilizers, antidepressants) 16. Course intake of nootropic drugs in the previous 3 months 17. Communicative, sensory, motor, or any other deficiency that does not allow the patient to adequately assess their behavior and correctly fulfill the conditions of the study protocol. 18. The presence in the history of any significant, according to the physician-researcher, condition that prevents the inclusion of the patient in the study. 19. Participation in any clinical study in the previous 3 months 20. Employees of the study centres and their family members.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Montreal Cognitive Assessment (MoCA) scale score | 32 days | The MoCA test is a one-page 30-point test, ranging between 0 and 30, where 0 is the worst and 30 is the best result; a score of 26-30 or over is considered to be normal. Outcome measure is the change in the MoCA scale score by the end of the treatment course compared with the preoperative score. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Mini-Mental State Examination (MMSE) follow-up score | 90 days | MMSE test is a 30-point questionnaire; any score greater than or equal to 24 points (out of 30) indicates a normal cognition; below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment. Outcome measure will be the change of MMSE scale score by the end of the follow-up period |
| Montreal Cognitive Assessment (MoCA) follow-up | 90 days | The MoCA test is a one-page 30-point test, ranging between 0 and 30, where 0 is the worst and 30 is the best result; a score of 26-30 or over is considered to be normal. Outcome measure is the change of the MoCA scale score by the end of the follow-up period |
| Median group Mini-Mental State Examination (MMSE) score | day 7, 32, 90 | MMSE test is a 30-point questionnaire; any score greater than or equal to 24 points (out of 30) indicates a normal cognition; below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment. Outcome measure will be the difference between median group total scores on the MMSE scale. |
| Median Montreal Cognitive Assessment (MoCA) scale score | day 7, 32, 90 | The MoCA test is a one-page 30-point test, ranging between 0 and 30, where 0 is the worst and 30 is the best result; a score of 26-30 or over is considered to be normal. Outcome measure is the difference in median group values of the MOCA scale |
| Proportion of postoperative delirium | day 3-6 | The proportion of patients who developed postoperative delirium in the first 96 hours after surgery according to the results of CAM-ICU |
| The Mini-Mental State Examination (MMSE) scale | 32 days | MMSE test is a 30-point questionnaire; any score greater than or equal to 24 points (out of 30) indicates a normal cognition; below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment. Outcome measure will be the change of MMSE scale score by the end of the treatment course compared to the preoperative score |
| Mortality | day 32 | Mortality in the postoperative period in the experimental and control groups |
| Postoperative cognitive decline | day 32, day 90 | The proportion of patients with a decrease in the results of two or more neuropsychological tests by more than 20% by the end of the treatment course and by the end of the follow-up period compared the baseline values |
| Quality of life score | day 90 | Change in the overall score for the EQ-5D questionnaire for assessing the quality of life |
| Independence and activity | day 32 | The proportion of patients dependent in at least two daily functions according to the results of the Katz Daily Activity Index at the end of the treatment course |
| Anxiety/depression | day 32, day 90 | The group average score by Hospital Anxiety and Depression Scale (HADS) at the end of the treatment course and at the end of the follow-up period. The HADS is a fourteen item scale, a person can score between 0 and 21 for either anxiety or depression, where scores on each scale can be interpreted in ranges: normal (0-7), mild (8-10), moderate (11-14) and severe (15-21). |
| Length of stay in the ICU | day 32 | Length of stay in the ICU |
Countries
Russia
Outcome results
None listed